Lost 70%, but the numbers look too good now.

A harrowing financial pullback almost sidelined this analyst completely. After taking a severe 70% hit on a past venture, scrutiny turned toward undervalued small-market-cap biopharma. The current target presents a compelling setup: a company sitting on $159 million in cash against a dizzying market capitalization barely above that mark. Witness the detailed breakdown that convinced an investor to jump back into the volatile world of biotech, picking up shares right at the $1.90 level. This is a masterclass in finding true underlying value after enduring significant pain.
#Biotech #Investing #Stock #Market #Undervalued #Stocks #Biopharma #Investment #Strategy #Small #Cap #Stocks #Value #Investing #Stock #Analysis

Видео Lost 70%, but the numbers look too good now. канала Dan Sfera